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Peptides are versatile biopolymers composed of 2–100 amino acid
residues that present a wide range of biological functions and
constitute potential therapies for numerous diseases, partly due
to their ability to penetrate cell membranes. However, their mecha-
nisms of action have not been fully elucidated due to the lack of
appropriate tools. Existing light-emitting probes are limited by their
cytotoxicity and large size, which can alter peptide structure and
function. Here, we describe the available fluorescent, biolumines-
cent, and chemiluminescent probes for labeling peptides, with a
focus on minimalistic options.INTRODUCTION
Peptides display numerous biological activities, including antimicrobial, immuno-
modulatory, analgesic, anti-inflammatory, antioxidant, and anticancer properties.1,2
Depending on their physicochemical properties, peptides can attack the physical
integrity of cellular membranes through different modes of action and/or translocate
into the cell, interfering with intracellular targets and eventually blocking biological
processes vital to the cell.3 However, the multifunctional mechanisms of action
(MoA) of peptides are not entirely understood. Fluorescent and luminescent
methods can help elucidate the MoA of these molecules (Figure 1A), but the lack
of suitable fluorescent probes, mainly due to their large size and toxicity, has tradi-
tionally limited this area of research. In this review, we provide an overview of
recently described fluorescent and luminescent probes that may help elucidate
the MoA of antimicrobial peptides (AMPs) specifically, and peptides more broadly.1Machine Biology Group, Departments of
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Non-natural Fluorescent Amino Acids (FlAAs)
Amino acid residues, such as tryptophan (Trp), tyrosine, and phenylalanine, are
intrinsically fluorescent due to their aromatic side chain groups (Table 1).4 Trp is
the most commonly used amino acid for this purpose and has been used as a fluo-
rescent probe for labeling peptides and studying protein folding.5 However, the
spectroscopic properties of Trp are complex, due to its multi-exponential fluores-
cence decay with two different lifetimes (t1/2, Table 1), caused by the emission
from two nearly identical electronic transitions.6 Efforts have been made to try to
modify the chemical structure of natural FlAAs to improve their fluorescent proper-
ties (i.e., fluorescent quantum yield [FFL], t1/2, and Stokes shift).
4 FFL can be defined
as the ratio between the number of molecules that undergo radioactive decay from
the excited singlet state (S1) to the ground state (S0) and the total number of mole-
cules that are excited to S1 by photon absorption.
7 Light-emitting probes display
significant changes in their spectroscopic properties when exposed to environments
with different polarity. When a fluorescent probe interacts with the cell membrane,
its fluorescence emission intensity increases, and a hypsochromic shift of theCell Reports Physical Science 1, 100257, December 23, 2020 ª 2020 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Biomedical Applications of Peptides Labeled with Light-Emitting Probes
(A) Study of the mechanisms of action of antimicrobial peptides.
(B) Tracking of infections (e.g., invasive pulmonary aspergilloses [IPA] caused by Aspergillus
fumigatus).
(C) Localization and diagnosis of single cancer cells and tumors (some peptides can interact
specifically with important biomarkers of cancer cells and/or tumors (e.g., interaction of the labeled
peptide GE-137 with the protein tyrosine kinase c-Met, overexpressed in colorectal cancer).
(D) Bioimaging.
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OPEN ACCESS Reviewmaximum emission wavelength can be observed. These phenomena occur because
the cell membrane environment is more viscous and less polar than water. Thus, the
probe becomesmore rigid (i.e., less vibrational modes), leading to a reduction in the
thermal deactivation of excited states and increasing the amount of energy associ-
ated with radiative decay.
Non-fluorescent amino acids can became fluorescent by structural modifications, al-
lowing their use as probes that minimally disturb peptide structure and function.4,8,9
Non-natural FlAAs have been developed for insertion at specific positions of the
peptide sequence without altering its biological function, both using solid-phase
peptide synthesis and through genetic encoding.4 For example, cyanotryptophans
have been synthesized to improve the fluorescent properties of Trp by the insertion
of cyanide (CN), an electron-withdrawing substituent.10–12 Specifically, 5-cyano-
tryptophan showed an increased Stokes shift and enhanced sensitivity to hydration
compared to Trp (Table 1; Figure 2A).13 5-Cyanotryptophan presents a FFL of 0.01
and a predominant t1/2 of 0.4 ns in water (Table 1). However, in other solvents, such
as ethanol (FFL = 0.17 and t1/2 = 6.8), acetonitrile (FFL = 0.13 and t1/2 = 3.1), and 1,4-
dioxane (FFL = 0.11 and t1/2 = 6.0), 5-cyanotryptophan displays greater FFL and pre-
dominant t1/2 compared to aqueous solution.
13 When mastoparan-X, an AMP from
the mastoparan family that includes dozens of small cationic a-helical peptides, is
labeled with 5-cyanotryptophan, it adopts a relatively unstructured conformation
in water but remains folded into an a-helix similar to that of unlabeled masto-
paran-X in the presence of dodecylphosphocholine micelles.13 The 5-cyanotrypto-
phan-labeled mastoparan-X exhibits a maximum fluorescence emission wavelength
at 391 nm in water, with low fluorescence emission intensity.13 However, in the pres-
ence of dodecylphosphocholine micelles, this labeled peptide presents an
increased fluorescence emission intensity with a hypsochromic shift (from 391 to
372 nm).13 These changes in the fluorescence profile of 5-cyanotryptophan-labeled
mastoparan-X allow monitoring of its biological binding process.13 Another
example is L-4-cyanotryptophan (Figure 2A), a Trp derivative that has been used
to label the AMP pHLIP within its N-terminal extremity.14 This derivative exhibits
higher FFL in aqueous solution, a larger fluorescence t1/2 and Stokes shift, and
increased photostability compared to Trp (Table 1).11,14 Due to its fluorescent2 Cell Reports Physical Science 1, 100257, December 23, 2020
Table 1. Properties of Light-Emitting Probes
Probe Exact Mass (g mol1) labs. (nm) lem.(nm) Dl (cm
–1) E (M–1 cm–1) FFL t1/2 (ns) Ref.
Natural fluorescent amino acids
Trp 204.09 280 348 6,980 5,600 0.20 3.1 and 0.5 Ghisaidoobe and Chung6
Tyrosine 181.07 274 303 3,500 274 0.14 3.6 Ghisaidoobe and Chung6
Phenylalanine 165.08 257 282 3,450 200 0.04 6.4 Ghisaidoobe and Chung6
Non-natural fluorescent amino acids
L-4-Cyanotryptophan 229.09 312 420 8,240 6,000 0.80 13.7 Hilaire et al.11
5-Cyanotryptophan 229.09 280 391 10,140 5,500 0.01 0.4 Markiewicz et al.13
Trp(BODIPY) 526.24 503 517 540 121,000 0.22c – Mendive-Tapia et al.15
Trp(redBODIPY) 594.21 570 590 600 52,950 – – Subiros-Funosas et al.17
Acd 282.10 400 450 2,780 5,700 0.95 15.0 Sungwienwong et al.21
Mcm 263.08 320 390 5,610 – – – Sungwienwong et al.21
Aad 297.11 425 530 4,660 – – – Sungwienwong et al.21
Fluorescent organic probes
GFP 27,000 395/475 508 5,630/1.370 56,000 0.60 – Johnson and Straight23
Rhodamine B 478.20 554 576 690 106,000a 0.65b 1.5–1.7 Kubin and Fletcher27
and Kristoffersen et al.28
Fluorescein (dianion) 330.05 490 515 990 76,900 0.93 4.1 Sjöback et al.29
Coumarin 343 285.10 443 462 930 44,300b 0.63b 4.6 Pant and Girault34
DMAQs 282.09–410.25a 274–498 469–550 – – – – Jun et al.35
CPX 488.21 419 542 5,420 – – – Jun et al.36
HC 411.22 670 718 1,000 100,225 0.43b – Jin et al.44
Cy5** 887.22 648 675 620 – – – Burggraaf et al.50
Cy5.5 583.33 680 708 580 – – – Joshi et al.51
Values corresponding to the exact mass, maximum absorbance wavelength (labs.), maximum emission wavelength (lem.), Stokes shift (Dl), molar absorptivity (ε),
fluorescence quantum yield (FFL), and lifetime (t1/2) are provided for natural fluorescent amino acids, non-natural fluorescent amino acids, and fluorescent organic
probes. All of the fluorescence properties presented in this table were established in aqueous solution, except when specified: a(methanol), b(ethanol), and
c(membrane environment).
ll
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energy transfer (FRET) pair with 3,3¢-dioctadecyloxacarbocyanine perchlorate to
determine the rate constant for peptide-membrane binding.14
Another Trp-derived synthetic amino acid, Trp(BODIPY), was designed by conju-
gating Trp and boron-dipyrromethene (BODIPY) fluorogen via a spacer-free C-C
bond (Figure 2A; Table 1).15 Trp(BODIPY) has been used to label short peptides
such as PAF26, an antimicrobial hexapeptide with high affinity toward the Asper-
gillus fumigatus cell membrane.15 This fungus is responsible for invasive pulmonary
aspergilloses (IPA), with a mortality rate of up to 40%.16 The high stability of this
probe allowed ex vivo imaging of human pulmonary tissue during an IPA infection
with minimal fluorescence background from the tissue (Figure 1B).15 Red-emitting
fluorescent probes have attracted attention due to their less-energetic emission,
which causes less damage to biological samples. Recently, the first red-emitting
Trp-based fluorescent amino acid, also containing BODIPY in its structure (Trp(red-
BODIPY); Figure 2A; Table 1), was synthesized and coupled to the hydrophobic
portion of a cyclic peptide to label the protein keratin 1, a diagnostic marker for
breast cancer (Figure 1C).17 Computational and experimental results showed that
the unlabeled peptide and the same peptide labeled with Trp(redBODIPY) pre-
sented similar values of relative binding affinity with keratin 1 (kd 1.0 mmol L1).17Cell Reports Physical Science 1, 100257, December 23, 2020 3
Figure 2. Fluorescent Probes for Peptide Labeling
Schematic representation of the relationship between molecular structure (depending on the
identity of the substituents), the color of the light emitted through the fluorescence decay, and the
maximum emission wavelength (lem.) of (A) non-natural fluorescent amino acids and (B) fluorescent
organic probes.
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BODIPY TR (at the amino group within the side chain of D-Lys) presented a 5-fold
weaker binding profile.17 Therefore, Trp(redBODIPY) interfered less with the pep-
tide-keratin 1 affinity process than BODIPY TR.17
The first spin label probe incorporated through a peptide bond was TOAC (2,2,6,6-
tetramethyl-N-oxyl-4-amino-4-carboxylic acid), a non-natural amino acid containing
a stable paramagnetic nitroxide radical (Figure 2A).18 Recently, TOAC was used to
label tritrpticin (TRP3), an AMP that acts by a toroidal pore mechanism and has at
least four different conformations in solution, with a turn-turn structure in its C-termi-
nal portion stabilized in the presence of micelles, which can be observed by NMR.19
TRP3 was labeled with TOAC at its N-terminal extremity (TOAC0-TRP3), and inter-
nally, by substituting the proline residue in position five (TOAC5-TRP3) to elucidate
its mechanism of action (Figure 1A), activity, toxicity, and conformational proper-
ties.20 Both TOAC-labeled peptides presented similar activity against Escherichia
coli (minimum inhibitory concentration [MIC] = 4.0, 1.3 and 1.9 mmol L1 for
TOAC0-TRP3, TOAC5-TRP3, and TRP3, respectively), and Micrococcus luteus (MIC
4.0 and 1.1 mmol L1 for TOAC-labeled peptides and TRP3, respectively)
compared to non-labeled TRP3.20 All of the peptides showed low hemolytic activity
(<5%) at concentrations 25-fold higher than their MIC. In addition, compared to its
template TRP3, the labeled N-terminal extremity led to a similar complex structure,
but was more effective at membrane permeabilization. On the contrary, when TRP3
was labeled in the middle of its sequence, it exhibited similar mechanisms of action
as when unlabeled but with an extended conformation.20
Acridonylalanine (Acd, Figure 2A) is another widely used non-natural FlAA. Acd can
be used for labeling and as a pair for FRET or photoinduced electron transfer.21 It
displays a high FFL in water, long fluorescence t1/2, and high photostability,
compared to other non-natural FlAAs (Table 1).21 Acd and the small probe methox-
ycoumarinylalanine (Mcm; Figure 2A; Table 1) were used as a FRET pair to study pro-
tein distances at a range of 15–40 Å. Trp labeling with the FRET pair Mcm/Acd has
been used to monitor multiple interactions simultaneously (e.g., protein/protein in-
teractions and conformational changes) in three-color FRET.22 However, Acd has a
small Stokes shift and its emission spectra shows a significant overlap with that of4 Cell Reports Physical Science 1, 100257, December 23, 2020
Figure 3. Size Distribution of Light-Emitting Probes Used for Peptide Labeling
Comparison between the structure and size of different types of fluorescent probes that are
currently applied for labeling peptides.
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cridonylalanine, Aad) was synthesized and presented a bathochromic shift at its
maximum emission wavelength with the insertion of an amino group as substituent
(Figure 2A; Table 1).21 Aad was shown to be a better FRET acceptor than Acd when
used with the Mcm donor. Furthermore, its increased Stokes shift allowed the use of
Aad as a FRET donor for red wavelength dyes and microscopy applications using
conventional filter sets for cyan fluorescent protein excitation and yellow fluorescent
protein emission.21
Fluorescent Organic Probes
Green fluorescent protein (GFP, Figure 2B; Table 1), isolated from the jellyfish Ae-
quorea victoria, is the most common fluorophore in molecular biology and biotech-
nology, and is widely used as a marker for gene expression and protein localization
in living and fixed tissues.23 Other self-labeling fluorescent proteins (FPs), such as
SNAP-tag and HaloTag, can be conjugated to peptides or proteins to investigate
how they associate with cell membranes, or can even be directly coupled to living
cells.23,24 However, wild-type FPs are usually found in their oligomeric form, showing
higher toxicity and decreased ability to interact with their target biomolecules (e.g.,
proteins, peptides), leading to mistargeting and lower selective binding, thus
requiring artificial monomerization, and consequent loss of brightness and stabil-
ity.23 Moreover, FPs are large and hydrophobic (Figure 3), and when they are incor-
porated into small target molecules such as peptides, they can cause undesirable
aggregation and changes in physicochemical properties and biological activity.25,26
Fluorescent organic probes, such as xanthene dyes (e.g., rhodamine B, fluorescein;
Figure 2B), represent an alternative for peptide labeling as they are smaller in size
(Figure 3) and exhibit greater water solubility and FFL (Table 1).
27–29 Nonetheless,
such organic probes may also compromise the activity of peptides, which are sensi-
tive to alterations in structure and physicochemical properties. Hydrophobicity and
net charge are the most relevant features affected in these cases and can yield pep-
tides with high toxicity (Figure 3). For instance, an oligopeptide (EVP50) labeled with
rhodamine B (Figure 2B; Table 1) showed lethal toxicity toward zebrafish larvae
(lethal dose 50% [LD50] = 6 mmol L
1) accumulating inside the cells within minutes,
and interfering with calcium homeostasis and membrane dysfunction, whereas the
unlabeled EVP50 did not display cytotoxicity in vitro or in vivo.30 Crotamine is a
cell-penetrating peptide (CPP) with antitumor, antimicrobial, antifungal, and anti-
parasitic activities at micromolar concentrations, which also exhibits toxicity against
eukaryotic muscle cells and tissues at millimolar concentrations.31 The rhodamine
B-labeled crotamine was toxic at micromolar concentrations (4.0 mmol L1),
translocating the vitelline membrane, and accumulating in the zebrafish yolk sac,Cell Reports Physical Science 1, 100257, December 23, 2020 5
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(< 1.0 mmol L1), the labeled crotamine caused malformation in embryos, delayed
or completely halted hatching, decreased cardiac functions, and attenuated swim-
ming distance of zebrafish.32 Xanthene dyes can also be used to study the MoA of
AMPs (Figure 1A); however, their hydrophobicity may decrease their antimicrobial
activity and alter the MoA of these peptides.33 The enteric peptide a-defensin
HD5 presents antimicrobial activity by generating bleb conformations and elonga-
tion of the treated bacteria, suggesting a different MoA from classical membrane-
disrupting peptides.33 To study its MoA against bacterial cells (Figure 1A), a-HD5
was labeled with rhodamine B, coumarin 343, and fluorescein at different positions
within its sequence (Figure 2B; Table 1).33,34 Rhodamine B-labeled a-HD5 enabled
tracking of the peptide to the poles and cytoplasm division site of the bacterial
cell, indicating that a-HD5 operates internally within the cell and targets cell division.
However, labeling with rhodamine B repressed the antibacterial activity of this pep-
tide when compared with its unlabeled counterpart.33
Despite the discovery of a number of fluorescent probes for peptides, several issues
still need to be addressed to yield probes with high sensitivity and FFL that lack
toxicity, can be easily coupled to the peptide backbone, and do not alter structure,
physicochemical properties, or biological activity. Overcoming these issues is still a
challenge, but progress has been made. Recently, small and adaptable quinoline-
based probes containing three functionalizable domains were synthesized by a sim-
ple and efficient methodology.35 More than 20 derivatives were designed from a
‘‘core’’ scaffold of dimethylamino quinoline (DMAQ; Figure 2B; Table 1). The deriv-
atives exhibited unusual pH sensitivity in multicolor live-cell imaging.35 Also, a
water-soluble, cell-permeable, and non-cytotoxic photoconvertible small fluores-
cent probe called CPX was synthesized (Figure 2B; Table 1).36 CPX was coupled at
three different positions within the a-synuclein protein through Huisgen 1,3-dipolar
azide-alkyne cycloaddition and, due to its small size, overcame the common limita-
tions of FPs in studies involving a-synuclein aggregate dynamics (Figure 3).36 More-
over, the precursor of this probe can be conjugated to other biomolecules through
nucleophilic displacement of the iodide.36
Proteolytic degradation is a major obstacle in the development of new peptide-
based drugs. Fluorescent quenchers, such as thioamides, can be used to track
and reduce proteolytic degradation, thus stabilizing and increasing the in vivo serum
half-life of peptides.37,38 Cysteine protease can be tracked through the synthesis of
thioamide-labeled peptides.39 When the peptide is cleaved, the thioamide group
stops quenching and fluorescence can be observed. The proteolytic degradation
of 5 papain families was reduced when thioamide was placed near or exactly at
the scissile bond of the peptide backbone, making the peptide 750-fold more
stable.39
Fluorescent probes are limited in vivo (Figure 1D), particularly when applied in hu-
mans, due to thematrix interference by autofluorescence and limited tissue penetra-
tion (1–2 mm) when their maximum emission wavelength is <650 nm.40 To overcome
these hurdles, nonlinear optical microscopy techniques, such as two-photon micro-
scopy, have been used for high-resolution imaging in tissues, enabling better tissue
penetration using two-photon probes.41 However, non-toxic probes with effective
two-photon properties that absorb long-wavelength excitation light and are used
at low concentrations without causing tissue damage are still needed. Thus, novel
noninvasive near-infrared (NIR) fluorescent probes, which emit in the NIR region,
650–900 nm, are urgently needed for monitoring enzymatic activities and for cancer6 Cell Reports Physical Science 1, 100257, December 23, 2020
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autofluorescence and light scattering, generate minimal photodamage to biological
samples, and undergo deep-tissue penetration (1–10 cm).42 The NIR probe HC (Fig-
ure 2B; Table 1) has been successfully applied for the detection of b-glucuronidase
(GLU) activity, an important biomarker for cancerous cells and the intestinal meta-
bolism of drugs (Figure 1C).43,44 HC can be used to visualize GLU in a tumor-bearing
mouse model and in the intestinal tract of living mice and zebrafish with high selec-
tivity and sensitivity, desirable cell penetration, and low cytotoxicity.44
NIR cyanine probes are used for detecting mRNA,45 H2S,
46 nucleic acid,47 and mito-
chondrial cysteine,48 as well as for labeling DNA,49 enzymes, and peptides that spe-
cifically target overexpressed proteins in cancer, such as tyrosine kinase c-Met (Fig-
ure 1C).50 The NIR cyanine probe (Cy5**; Figure 2B; Table 1) has been used for
labeling a 26-amino-acid-residue-long cyclic peptide that targets the human tyro-
sine kinase c-Met, a biomarker for early-stage colorectal cancer (Figure 1C).50 The
labeled peptide, GE-137, was tested in vitro, in vivo (Figure 1D), and in a pilot study
with human patients by intravenous administration. GE-137 was safe in humans and
enabled the visualization of 36 hyperplastic lesions and 8 serrated polyps by colo-
noscopy.50 Another cyanine probe (Cy5.5; Figure 2B; Table 1) was used for labeling
a peptide (KSP*) whose amino acid sequence was modified using structural
modeling based on mimotopes to optimize its hydrophilic and hydrophobic interac-
tions with HER2, a receptor that is overexpressed in tumoral colorectal cells of sessile
serrate and sporadic adenoma in the proximal colon (Figure 1C).51 The labeled pep-
tide helped localize spontaneous adenomas and enabled real-time in vivo imaging
(Figure 1D) with high binding affinity, low signal-to-noise ratio, and deeper tissue
penetration when compared to the same peptide labeled with fluorescein
isothiocyanate.51
Radionuclides
Radionuclides that emit a positron when they undergo radioactive decay such as
68Ga, 18Fl, 13N, and 15O can be used for labeling peptides in positron emission to-
mography/computed tomography (PET/CT) studies.52 Themain advantage of radio-
nuclides over FPs and fluorescent organic probes for peptide labeling is their
reduced size (Figure 3). The AMP ubiquicidin (UBI), for example, displays low toxicity
toward mammalian cells, binds specifically to the bacterial cell membrane, and
is widely used in nuclear imaging for infection detection when labeled with
68Ga.53–56 UBI has been functionalized with a chelator (1,4,7-triazacyclononane-
1,4,7-triacetic acid [NOTA]) and complexed with 68Ga to study its cytotoxicity
in vitro, in addition to its biodistribution, pharmacokinetics, and radiation dosimetry
in non-human primates. These results led to the first-in-human evaluation of infec-
tion diagnosis using PET/CT imaging.57,58 Ga-NOTA-UBI lacked toxicity, displayed
favorable biodistribution (with predominant urinary excretion), and safety for human
applications, as it was able to detect bone and soft-tissue infection with no side ef-
fects observed.57
Presently, some radionuclides, including 111In, 90Y, and 177Lu, have been used in
peptide receptor radionuclide therapy (PRRT) as a strategy for the treatment and
diagnosis of neuroendocrine tumors, metastatic pheochromocytoma, and paragan-
glioma (PPGL).59 PRRT involves the use of radiolabeled somatostatin analogs that
bind to somatostatin receptors, which are overexpressed by neuroendocrine
tumors and PPGL (Figure 1C).59 This radiotherapy allows the delivery of radionu-
clides to tumor cells, dosimetry studies, and localization of tumors. The most used
somatostatin analog peptide is octreotide labeled with 177Lu (177Lu-DOTATATE)Cell Reports Physical Science 1, 100257, December 23, 2020 7
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An analysis from the NETTER-1 trial, an international phase III study in patients with
midgut neuroendocrine tumors, demonstrated that treatment with 177Lu-DOTA-
TATE significantly improved progression-free survival and global health status in pa-
tients with progressive midgut neuroendocrine tumors compared with a high-dose
of octreotide. Treatment reduced insomnia, fatigue, pain, loss of appetite, and diar-
rhea.62 Nonetheless, the radiation generated during PRRT therapy may produce se-
vere side effects.59
Malignant prostate epithelial cells overexpress gastrin-releasing peptide receptor
(GRPr) and prostate-specific membrane antigen (PSMA) at levels up to 1,000-fold
higher than normal prostate cells.63 Small peptides that bind selectively to PSMA
can be used as an alternative therapy to deliver cytotoxic drugs to malignant sites
(Figure 1C).63–66 These peptides have been labeled with radionuclides using che-
lators such as DOTA, NODAGA, or HBED-CC. The peptide bombesin (BN), for
example, binds selectively to GRPr, an observation that led to the development
of a number of BN-based radiopharmaceuticals for prostate cancer diagnosis.67,68
A 177Lu-labeled BN peptide (177Lu-iPSMA-BN) was synthesized, and its ability to
target PSMA and GRPr was evaluated in vitro and in vivo. The resulting molecule
was considered a stable and specific radiopharmaceutical for prostate cancer.68
However, the pharmacokinetics of these therapeutic agents should be further
investigated, especially because radiotracers may accumulate in the pancreas
leading to side effects, particularly when administering high doses of radiolabeled
peptides.58
Nanoparticles
Nanoparticles (NPs; Figure 3) have been designed for tracking therapeutic biomol-
ecules, drug delivery, improvement of the solubility and half-life of certain drugs,
and for reducing immunogenicity.69 Peptide-based NPs with structure-induced fluo-
rescence represent a new strategy for biological imaging that allows imaging cells
and tissues without the need for fluorescent probes. Such NPs have been described
as functional nanoprobes because of their biological activity and fluorescent prop-
erties.70 NIR fluorescent cyclic peptide NPs (f-PNPs) were designed and synthesized
for imaging and drug delivery applications in esophageal cancer.71 f-PNPs were con-
jugated with RGD (i.e., Arg-Gly-Asp) moieties for the selective targeting of esopha-
geal cancer cells via integrin receptors, and embedded with epirubicin (EPI), a
chemotherapeutic drug that can cause side effects such as cardiac toxicity, bone
marrow suppression, and secondary leukemia.71 The resulting complex was used
to monitor EPI delivery in tumors by NIR fluorescence (NIRF), demonstrating a signif-
icant reduction in cardiotoxicity and enhanced antitumor activity in relation to EPI
alone.71 Another interesting alternative is the use of polymers that can emit strong
fluorescence by aggregation-induced emission (AIE).72 Novel nanoengineered pep-
tide-grafted hyperbranched polymers (NPGHPs) were synthesized by ring-opening
polymerization on the surface of the hyperbranched polyamide amine (H-PAMAM),
a polymer containing tertiary amines that, when oxidized, becomes fluorescent via
AIE.73,74 NPGHPs were used as fluorescent probes to visualize antibacterial activity,
allowed monitoring of E. coli with a limit of detection of 104 colony-forming units
(CFU) mL1, and showed potent antimicrobial activity against E. coli, Pseudomonas
aeruginosa, Staphylococcus aureus, and Bacillus subtilis. The hemolytic activity of
NPGHPs was examined using fresh anticoagulant rabbit blood, presenting 2.13%
hemolysis rate when using 200 mg mL1 of NPGHPs. Also, toxicity was verified using
mouse embryonic osteoblast precursor cells, showing >80% cell survival rate at a
concentration ranging from 25 to 200 mg mL1 after 3 days.738 Cell Reports Physical Science 1, 100257, December 23, 2020
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core usually based on zinc or cadmium. QDs can display antimicrobial activity and
inhibit biofilm formation.75 QDs represent a promising alternative for the labeling
of peptides, proteins, oligonucleotides, and polysaccharides in addition to being
used for imaging single cells, tissue, and tumors.76 QDs have advantages over
organic probes due to their satisfactory Stokes shifts, which increases as their diam-
eter decreases, t1/2 of 10–40 ns, highFFL, large extinction coefficients (10- to 50-fold
higher than organic probes), and broad excitation and emission spectra.42,77–79 Two
AMPs, KG18 and VR18, were conjugated with tungsten disulfide (WS2) QDs for ap-
plications in antimicrobial therapy, diagnosis, and bioimaging (Figure 1D).80 The re-
sulting conjugations demonstrated antibiofilm potency (at 200 mmol L1) and 2-fold
higher antimicrobial activity (2.5 mmol L1) than non-conjugated peptides against
P. aeruginosa and Candida albicans, causing membrane rupture, loss of
morphology, and metabolite release within a few minutes of treatment. The larger
surface area of the conjugated peptide QDs, compared to the peptide alone,
caused peptide clustering and consequently more efficient membrane disruption.
Furthermore, the use of QDs enabled monitoring the precise location of QD-
KG18 within C. albicans cells as early as 10 min after incubation, whereas both
AMPs (i.e., KG18 and VR18) labeled with fluorescein isothiocyanate remained at
the cell surface even after 60min of incubation.80 Nevertheless, QDs have limitations
when continuously exposed to light, generating a ‘‘blinking effect’’ and toxicity,
likely due to the release of metal ions or reactive oxygen species. Moreover, QDs
can translocate cellular membranes and interact with functional biomolecules
migrating to various organs and tissues, ultimately causing damage.42,76 Different
strategies have been designed in an attempt to overcome these limitations, such
as coating QDs with polyethylene glycol, dihydrolipoic acid, and peptides, to in-
crease stability and protect the core from degradation.76 The AMP indolicidin was
used to coat and protect the metallic core of toxic antimicrobial QDs, reducing their
toxicity.81 The antimicrobial activity of these indolicidin-coated QDs against
S. aureus, P. aeruginosa, E. coli and Klebsiella pneumoniae was compared with
that of QDs and indolicidin alone.81 In addition, ecotoxicological tests were per-
formed for QDs and indolicidin-coated QDs to evaluate the immobilization of
Daphnia magna, the bioluminescence (BL) inhibition of Vibrio fisheri, the mutage-
nicity activity of Salmonella typhimurium TA 100, the genotoxicity on Daphnia ma-
gna, as well as analysis of reactive oxygen species and antioxidant enzyme activity
on Daphnia magna.81 The indolicidin-coated QDs showed enhanced antimicrobial
activity compared to QDs and indolicidin, mainly against Gram-negative bacteria.
QDs coated with indolicidin exhibited decreased ecotoxicity against Daphnia ma-
gna, compared to QDs (from 67% of mortality for QDs to 20% for coated QDs),
bioluminescence inhibition in Vibrio fisheri (40% with 5.0 nmol L1), and no muta-
tions in S. typhimurium TA 100. However, both QDs alone and indolicidin-coated
QDs induced deleterious effects such as oxidative stress and DNA damage.81
Chemiluminescence (CL) and BL Imaging
CL is the generation of light resulting from an exothermic chemical reaction.82
When this phenomenon occurs inside a living organism, it is called BL.82 Many
CL and BL transformations have been thoroughly studied at the molecular level,
both experimentally and using theoretical data.82 Light is produced when the elec-
tronic excited state of a molecule decays through the emission of a photon. Such
emissive excited states can be obtained by a chemical transformation, usually
involving a multistep complex sequence of reactions.82 Associated with peptides,
CL and BL systems have been extensively used for analytical purposes, as dis-
cussed recently elsewhere.83 Here, we focus on how CL and BL can be appliedCell Reports Physical Science 1, 100257, December 23, 2020 9
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to peptides.
To produce the electronic excited state, one can rely on an electrochemical process
coupled to chemical transformation known as electrochemiluminescence (ECL). ECL
has been used to detect and quantify peptides and other target molecules.83,84
Moreover, information regarding dynamic aspects, such as intracellular uptake
and the enzymatic activity of associated enzymes that are associated with peptides,
can be obtained using CL systems that involve cyclic peroxides as substrates or re-
action intermediates. The most commonly used cyclic peroxides are phenoxy-
substituted adamantylidene-1,2-dioxetanes,85–87 also known as Schaap’s 1,2-dioxe-
tanes (S12D; Figure 4).88 The phenoxy portion of the 1,2-dioxetane contains a
protecting group (also known as a trigger) that can be removed upon the addition
of an external reactant, triggering peroxide decomposition and the generation of
carbonyl fragments on the excited state, ultimately leading to CL emission.82,85
Modern approaches have used a self-immolative scaffold to enable the release of a
molecule of interest in situ, together with the generation of the CL signal. This has
been done with a self-immolative CL prodrug, containing S12D as a CL probe and
a peptide-derived chemotherapeutic agent (monomethyl auristatin E [MMAE])
with disassembling being triggered by b-galactosidase.86,87 Green 550 nm CL light
intensity increased with higher concentrations of MMAE, allowing for real-time
monitoring of endogenous enzymatic activity in mouse tumors overexpressing
b-galactosidase.87 Caspase-3 activity has been measured by using S12D as a CL
probe, and para-aminobenzylic alcohol (PABA) as a self-immolative spacer attached
to an Asp-Glu-Val-Asp peptide responsive to the enzyme.89
Luminol is a well-known CL reagent.82 Although luminol itself is not a cyclic peroxide,
a six-membered peroxidic system is produced as an intermediate after reaction with
H2O2 in basic media and in the presence of metallic ions as catalysts.
82 The decom-
position of such six-membered peroxidic intermediate generates excited states and,
consequently, fluorescence emission.82 Some luminol derivatives have been applied
as CL probes for peptides instead of S12D.90,91 The Asp-Glu-Val-Asp tetrapeptide
was used as a linker of a luminol derivative (N-(4-aminobutyl)-N-ethylisoluminol
[ABEI]) coupled to functionalized magnetic beads (MBs; Figure 4).90 Upon peptide
cleavage by caspase-3, the released ABEI was recovered and its CL reaction with
H2O2 and Co
2+ was used for enzyme activity determination.90 The use of luminol de-
rivatives as CL probes does not allow for real-time measuring, in contrast to S12D
derivatives when they are used as sources for light production. Nonetheless, satura-
tion kinetics for the enzymatic activity of caspase-1 was observed with the flow-injec-
tion method, using ABEI molecules as a CL substrate coupled to gold nanoparticles.
The latter were recuperated from their conjugates with MBs and Tyr-Val-Ala-Asp,
previously treated with caspase-1.91
Recently, a chemo-fluoro-luminescent reporter (CFR) has been used in what the au-
thors referred to as ‘‘duplex imaging’’ of drug-induced hepatotoxicity (DIH),85,92
although in this case CL was not involved in peptide cleavage. The CFR comprised a
S12D molecule (with the phenoxy group protected by a triflate group [Tf]) connected
to a hemicyanine unit (CyU) with its hydroxyl group caged by a PABA linker, in turn con-
jugated to a caspase-3-cleavable Asp-Glu-Val-Asp peptide.92 Caspase-3 induced
cleavage of the amide bond between the tetrapeptide and the self-immolative
PABA linker, producing CyU after a 1,6-elimination; due to its structure, CyU exhibited
strong NIRF. In turn, S12D CL was triggered by Tf deprotection with superoxide anion,10 Cell Reports Physical Science 1, 100257, December 23, 2020
Figure 4. Molecular Structures of Chemiluminescent and Bioluminescent Probes, Assembledwith
Generic Peptides, Spacers, and Triggers (Structures Not Shown)
Chemical-induced decomposition of S12D and luminol, as well as the luciferin enzymatic reaction
with luciferase, generates the corresponding decomposition products and light at the given
wavelengths.
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CFR enables the longitudinal measurement of oxidative stress and cellular apoptosis in
a two-channel imaging method, hence the term ‘‘duplex imaging.’’92
Real-time imaging has been successfully performed using BL probes based on the firefly
luciferin/luciferase pair.94 Contrary to triggered-CL of peroxides such as S12D, light
emission in BL depends on the interaction of the luciferin substrate (Figure 4) with the
enzyme luciferase in the presence of molecular oxygen and cofactors such as ATP.82
A 1,2-dioxetanone high-energy intermediate is generated following a complex set of re-
actions, and the decomposition of this cyclic peroxide furnishes oxyluciferin in the elec-
tronic excited state.82 Deactivation of oxyluciferin generates light at 530 nm that can be
conveniently used for the quantification of cell transporters.94Cell Reports Physical Science 1, 100257, December 23, 2020 11
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cellular uptake (Figure 4). Firefly luciferin has been linked to an octa-arginine trans-
porter using a dithiol group, enabling the readout of real-time BL kinetics in a pros-
tate cancer cell line stably transfected with luciferase (PC3M-luc).94 Using HeLa pLuc
705 cells, the uptake intracellular kinetics of eight well-known CPPs linked to luciferin
were addressed and compared.95 Peptides MAP and TP10 displayed fast internali-
zation rates, resembling membrane-permeable free luciferin, whereas the slow up-
take of pVec, penetratin, M918, and EB1 were shown to be consistent with endocy-
tosis mechanism of internalization.95 Following the general concept of CPPs linked
to luciferin, firefly luciferase-specific inhibitors (FLICs)96 and split luciferin peptide
(SLP)97 methodologies have been proposed, the latter being suitable for real-time
imaging both in vitro and in vivo.
Concluding Remarks
Despite recent progress made in this research area, the development of suitable light-
emitting probes for labeling small molecules such as peptides remains a grand chal-
lenge. The lack of non-toxic light emitting probes for labeling peptides, while not
negatively affecting their specificity and biological and structural properties, has hin-
dered progress in this field. Here, we provide a summary of the latest efforts aimed
at developing small and appropriate fluorescent and luminescent probes. While there
is more work to be done to develop minimalistic structural modifications yielding lumi-
nescence and thus enabling imaging, we anticipate that such advances would accel-
erate the broad use of fluorescent approaches for disease diagnosis and detection.
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Ávila, E., Luna-Gutiérrez,M., and Isaac-Olivé, K.
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